JP2024544566A - ヒトパピローマウイルス（ｈｐｖ）抗原の発現の為のレンチウイルスベクター、並びにｈｐｖ誘発癌の処置におけるその実施 - Google Patents

ヒトパピローマウイルス（ｈｐｖ）抗原の発現の為のレンチウイルスベクター、並びにｈｐｖ誘発癌の処置におけるその実施 Download PDF

Info

Publication number
JP2024544566A
JP2024544566A JP2024528594A JP2024528594A JP2024544566A JP 2024544566 A JP2024544566 A JP 2024544566A JP 2024528594 A JP2024528594 A JP 2024528594A JP 2024528594 A JP2024528594 A JP 2024528594A JP 2024544566 A JP2024544566 A JP 2024544566A
Authority
JP
Japan
Prior art keywords
acid sequence
nucleic acid
lentiviral vector
protein
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024528594A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024544566A5 (https=
Inventor
シャルノー，ピエール
アンナ，フランソワーズ
モンコック，ファニー
ノワラ，アマンディーヌ
マジレッシ，ラレー
ドゥゲ，レティシア
ファート，イングリッド
Original Assignee
セラベクティス
アンスティチュ パスツール
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラベクティス, アンスティチュ パスツール filed Critical セラベクティス
Publication of JP2024544566A publication Critical patent/JP2024544566A/ja
Publication of JP2024544566A5 publication Critical patent/JP2024544566A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024528594A 2021-11-15 2022-11-14 ヒトパピローマウイルス（ｈｐｖ）抗原の発現の為のレンチウイルスベクター、並びにｈｐｖ誘発癌の処置におけるその実施 Pending JP2024544566A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP21306581 2021-11-15
EP21306581.6 2021-11-15
US202163279945P 2021-11-16 2021-11-16
US63/279,945 2021-11-16
EP22306119.3 2022-07-27
EP22306119 2022-07-27
PCT/EP2022/081839 WO2023084094A1 (en) 2021-11-15 2022-11-14 Lentiviral vectors for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers

Publications (2)

Publication Number Publication Date
JP2024544566A true JP2024544566A (ja) 2024-12-03
JP2024544566A5 JP2024544566A5 (https=) 2025-10-14

Family

ID=84536137

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024528594A Pending JP2024544566A (ja) 2021-11-15 2022-11-14 ヒトパピローマウイルス（ｈｐｖ）抗原の発現の為のレンチウイルスベクター、並びにｈｐｖ誘発癌の処置におけるその実施

Country Status (7)

Country Link
US (1) US20240415951A1 (https=)
EP (1) EP4433081A1 (https=)
JP (1) JP2024544566A (https=)
KR (1) KR20240124919A (https=)
AU (1) AU2022386715A1 (https=)
CA (1) CA3238020A1 (https=)
WO (1) WO2023084094A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025527186A (ja) * 2022-07-27 2025-08-20 セラベクティス ヒトパピローマウイルス（ｈｐｖ）抗原の発現のためのレンチウイルスベクターとｈｐｖにより誘発されるがんの処置におけるその実施

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116286982B (zh) * 2022-09-09 2024-01-30 广州凯普医药科技有限公司 一种hpv基因分型检测阳性参考品及其制备方法和应用
CN118344491B (zh) * 2024-05-03 2025-02-14 华中科技大学同济医学院附属同济医院 一种hpv16/18治疗性疫苗、制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69941703D1 (de) 1999-10-11 2010-01-07 Pasteur Institut Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen
DK2185192T3 (en) * 2007-08-03 2019-02-18 Pasteur Institut LENTIVIRAL TRANSFER VECTORS AND THEIR MEDICAL USES
CN113846062B (zh) 2014-07-25 2025-02-21 赛拉福柯蒂斯公司 用于嵌合抗原受体分子的调控表达的慢病毒载体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025527186A (ja) * 2022-07-27 2025-08-20 セラベクティス ヒトパピローマウイルス（ｈｐｖ）抗原の発現のためのレンチウイルスベクターとｈｐｖにより誘発されるがんの処置におけるその実施

Also Published As

Publication number Publication date
WO2023084094A1 (en) 2023-05-19
EP4433081A1 (en) 2024-09-25
US20240415951A1 (en) 2024-12-19
KR20240124919A (ko) 2024-08-19
AU2022386715A1 (en) 2024-05-16
CA3238020A1 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
JP6688535B2 (ja) ワクチン組成物
CN107921110B (zh) 治疗性hpv18疫苗
JP6655051B2 (ja) 発癌性ウイルスポリペプチド陽性腫瘍治療用ポリヌクレオチド
US20240415951A1 (en) Lentiviral vector for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers
US20110014221A1 (en) Hiv combination vaccine and prime boost
JP2025527186A (ja) ヒトパピローマウイルス（ｈｐｖ）抗原の発現のためのレンチウイルスベクターとｈｐｖにより誘発されるがんの処置におけるその実施
CN118354790A (zh) 用于表达人乳头瘤病毒(hpv)抗原的慢病毒载体及其在治疗hpv诱发癌症中的应用
JP2024509976A (ja) 抗原をｍｈｃ－ｉｉ経路にターゲティングし、宿主におけるｃｄ８＋及びｃｄ４＋ｔ細胞による防御免疫を誘導するレンチウイルスベクター
CN109923212B (zh) 用于表达乙肝病毒（hbv）抗原的慢病毒载体
WO2005002512A2 (en) Immunotherapeutic vaccine strategy
JPWO2007102326A1 (ja) アデノウイルス５型／３５型ベクターとワクシニアウイルスｍｖａベクターとの併用による強力な免疫誘導
de Mare et al. Viral vector-based immunization regimens: evidence for a central role of T cell competition
HK40007688A (en) Lentiviral vectors for expression of hepatitis b virus (hbv) antigens
EA042265B1 (ru) Поксвирусные векторы, кодирующие антигены вич, и способы их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251003